ABBVIE
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Drug Manufacturers - General
業務概覽 AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan addedseveral new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
公司地址 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
電話號碼 +1 847 932-7900
傳真號碼 --
公司網頁 https://www.abbvie.com
員工數量 57000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. David R. Purdue Principal Accounting Officer, Senior Vice President and Controller -- 20/02/2026
Mr. Demetris D. Crum Executive Vice President and Chief Human Resources Officer -- 20/02/2026
Dr. Roopal Thakkar, M.D. Executive Vice President, Research and Development and Chief Scientific Officer -- 20/02/2026
Dr. Azita Saleki-Gerhardt, B.S.,M.S.,PhD Executive Vice President and Chief Operations Officer 美元 1.02M 20/02/2026
Dr. Nicholas J. Donoghoe, M.D. Executive Vice President, Chief Business and Strategy Officer -- 20/02/2026
Mr. Robert A. Michael Chairman of the Board and Chief Executive Officer 美元 1.61M 20/02/2026
Mr. Jeffrey Ryan Stewart Executive Vice President and Chief Commercial Officer 美元 1.28M 20/02/2026
Mr. Scott T. Reents Executive Vice President and Chief Financial Officer 美元 1.07M 20/02/2026
Mr. Perry C. Siatis Executive Vice President, General Counsel and Secretary -- 20/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Frederick H. Waddell Independent Director 20/02/2026
Ms. Rebecca B. Roberts Independent Director 20/02/2026
Dr. Robert J. Alpern,M.D. Independent Director 20/02/2026
Mr. Thomas C. Freyman Independent Director 20/02/2026
Mr. Edward J. Rapp Independent Director 20/02/2026
Dr. Susan E. Quaggin, M.D. Independent Director 20/02/2026
Ms. Roxanne S. Austin Lead Independent Director 20/02/2026
Mr. Brett J. Hart Independent Director 20/02/2026
Mr. William H.L. Burnside Independent Director 20/02/2026
Ms. Melody B. Meyer Independent Director 20/02/2026
Mr. Robert A. Michael Chairman of the Board and Chief Executive Officer 20/02/2026
Mr. Thomas J. Falk Independent Director 20/02/2026
Ms. Jennifer L. Davis Independent Director 20/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:13)
代號 名稱 佔比% ▼ 持有日期
FDLFirst Trust Morningstar Div Leaders ETF<0.000001%22/06/2025
FDMOFidelity Momentum Factor ETF<0.000001%15/08/2025
FFFFounders 100 ETF<0.000001%22/12/2025
FFLCFidelity Fundamental Large Cap Core ETF<0.000001%23/06/2025
FMTMMarketDesk Focused U.S. Momentum ETF<0.000001%26/11/2025
GCOWPacer Global Cash Cows Dividend ETF<0.000001%27/02/2026
GDIVHarbor Dividend Growth Leaders ETF<0.000001%21/02/2026
GDOCGoldman Sachs Future Health Care Eq ETF<0.000001%19/11/2025
GSGOGoldman Sachs Growth Opportunities ETF<0.000001%17/11/2025
GUSEGoldman Sachs Enhanced U.S. Equity ETF<0.000001%11/02/2026
GVLEGoldman Sachs Value Opportunities ETF<0.000001%30/06/2025
GVLUGotham 1000 Value ETF<0.000001%27/02/2026
GVUSGoldman Sachs MktBt Russell LgCpValEqETF<0.000001%30/06/2025
HFGOHartford Large Cap Growth ETF<0.000001%01/01/2026
HGROHedgeye Quality Growth ETF<0.000001%07/01/2026
HKNDHumankind US Stock ETF<0.000001%24/11/2025
HLGEHartford Longevity Economy ETF<0.000001%11/06/2025
ICAPInfrastructure Capital Equity Income ETF<0.000001%27/02/2026
INCEFranklin Income Equity Focus ETF<0.000001%02/12/2025
INCMFranklin Income Focus ETF<0.000001%11/12/2025
  1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19    20    21   22    23    24    25  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.